Using our vaccine is easier because it is a single dose

Johnson & Johnson has submitted its global vaccine health data for clearance for emergency use.

While the company indicated that the United States Food and Drug Administration is currently evaluating its vaccine, it said, “Using our vaccine will be easier because it comes from a single dose.”

And if it gets the green light from the US Food and Drug Administration, this vaccine will be the third authorized in the United States, after the Pfizer-Bionic and Moderna vaccines.

This vaccine is particularly needed because it has two advantages which are logistically important, as it can be stored at normal refrigerant temperatures, which will greatly facilitate its distribution, and it is also administered to people with a single dose.

Critical station

The FDA must now establish a vaccine advisory committee that will issue an opinion after considering the data from clinical trials. He will be responsible for determining whether the benefits of the vaccine outweigh the risks of its use.

This step took about three weeks for the Pfizer / Bionic Moderna vaccine, but it may be faster this time around. Then, the green light for the vaccine will have to be given, possibly after consulting the advisory committee.

66% efficient

Johnson & Johnson has pledged to ship 100 million doses of its vaccine to the United States by the end of June.

Corona virus

The pharmaceutical giant announced earlier this month the first results of its clinical trials, which have been conducted on approximately 44,000 people in eight countries.

The company said the vaccine was generally 66% effective, while the effectiveness increased to 85% in preventing severe symptoms of the virus.

A disturbing product

But these results also raised concerns, as the vaccine was more effective in the United States (72%) than in South Africa (57%), as a mutated version of the virus emerged in that country and became its main source. to a large extent.

Experts see it as an indication that any future mutated copy could end up bypassing the immune defenses developed by current vaccines. This is another reason, they believe, to speed up vaccination campaigns.